Group 1 - The core point of the announcement is the decision by Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. to use part of the raised funds to permanently supplement its working capital, amounting to RMB 363.87 million [1][2]. - The decision was made during the third meeting of the fourth supervisory board held on August 4, 2025, with all three supervisors present, ensuring compliance with relevant laws and regulations [1][2]. - The use of the funds is aimed at reducing financial costs, enhancing operational efficiency, and improving profitability, while ensuring that it does not affect the construction of investment projects or the company's daily operations [1][2]. Group 2 - The proposal to use the raised funds requires approval from the company's shareholders' meeting, with a voting result of 3 votes in favor, 0 against, and 0 abstentions [2]. - The decision aligns with the regulations set forth in the "Regulations on the Supervision of Raised Funds by Listed Companies" and other relevant guidelines, ensuring no harm to the interests of the company or minority shareholders [1].
百诚医药: 第四届监事会第三次会议决议公告